News :: Kazia Therapeutics (KZIA)

Sep 9, 2022 8:00 am EDT KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT 24th ANNUAL GLOBAL INVESTMENT CONFERENCE

Sep 8, 2022 8:30 am EDT KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ESMO

Aug 5, 2022 8:46 am EDT KAZIA THERAPEUTICS REPORTS PROMISING INTERIM DATA FROM COMBINATION STUDY OF PAXALISIB WITH RADIOTHERAPY IN TREATMENT OF BRAIN METASTASES

Jul 12, 2022 8:15 am EDT KAZIA LAUNCHES NEW SCIENTIFIC ADVISORY BOARD COMPRISED OF WORLD-LEADING EXPERTS IN BRAIN CANCER

Jul 6, 2022 7:00 am EDT US FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER

Jun 17, 2022 8:00 am EDT US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER

Jun 13, 2022 7:00 am EDT POSITIVE DATA FOR PAXALISIB IN TWO CHILDHOOD BRAIN CANCERS PRESENTED AT 20TH ISPNO ANNUAL MEETING

Jun 7, 2022 7:00 am EDT PHASE II STUDY OF PAXALISIB IN BRAIN METASTASES ADVANCES TO EXPANSION STAGE IN BREAST CANCER BRAIN METASTASES COHORT

Jun 3, 2022 7:00 am EDT KAZIA PRESENTS POSITIVE FINAL DATA FROM PHASE II STUDY OF PAXALISIB IN NEWLY DIAGNOSED GLIOBLASTOMA AT ASCO CONFERENCE

May 31, 2022 7:20 am EDT GBM AGILE OPENS TO PAXALISIB IN EUROPE